Reporting of Outcomes in Gastric Cancer Surgery Trials:A Systematic Review by Alkhaffaf, Bilal et al.
                          Alkhaffaf, B., Blazeby, J., Williamson, P. R., Bruce, I., & Glenny, A. M.
(2018). Reporting of Outcomes in Gastric Cancer Surgery Trials: A
Systematic Review. BMJ Open, 8(10), [e021796].
https://doi.org/10.1136/bmjopen-2018-021796
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmjopen-2018-021796
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ at
https://bmjopen.bmj.com/content/8/10/e021796.info . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Alkhaffaf B, et al. BMJ Open 2018;8:e021796. doi:10.1136/bmjopen-2018-021796
Open access 
Reporting of outcomes in gastric cancer 
surgery trials: a systematic review
Bilal Alkhaffaf,1,2,3 Jane M Blazeby,4,5 Paula R Williamson,6 Iain A Bruce,7,8 
Anne-Marie Glenny9
To cite: Alkhaffaf B, 
Blazeby JM, Williamson PR, 
et al.  Reporting of outcomes in 
gastric cancer surgery trials: a 
systematic review. BMJ Open 
2018;8:e021796. doi:10.1136/
bmjopen-2018-021796
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
021796).
Received 22 January 2018
Revised 6 August 2018
Accepted 18 August 2018
For numbered affiliations see 
end of article.
Correspondence to
Bilal Alkhaffaf;  
 bilal. alkhaffaf@ mft. nhs. uk
Research
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
background The development of clinical guidelines for 
the surgical management of gastric cancer should be 
based on robust evidence from well-designed trials. Being 
able to reliably compare and combine the outcomes of 
these trials is a key factor in this process.
Objectives To examine variation in outcome reporting by 
surgical trials for gastric cancer and to identify outcomes 
for prioritisation in an international consensus study to 
develop a core outcome set in this field.
Data sources Systematic literature searches (Evidence 
Based Medicine, MEDLINE, EMBASE, CINAHL,  ClinicalTrials. 
gov and WHO ICTRP) and a review of study protocols of 
randomised controlled trials, published between 1996 and 
2016.
Intervention Therapeutic surgical interventions for gastric 
cancer. Outcomes were listed verbatim, categorised into 
groups (outcome themes) and examined for definitions and 
measurement instruments.
results Of 1919 abstracts screened, 32 trials (9073 
participants) were identified. A total of 749 outcomes 
were reported of which 96 (13%) were accompanied by 
an attempted definition. No single outcome was reported 
by all trials. ‘Adverse events’ was the most frequently 
reported ‘outcome theme’ in which 240 unique terms 
were described. 12 trials (38%) classified complications 
according to severity, with 5 (16%) using a formal 
classification system (Clavien-Dindo or Accordion scale). Of 
27 trials which described ‘short-term’ mortality, 15 (47%) 
used one of five different definitions. 6 out of the 32 trials 
(19%) described ‘patient-reported outcomes’.
Conclusion Reporting of outcomes in gastric cancer 
surgery trials is inconsistent. A consensus approach to 
develop a minimum set of well-defined, standardised 
outcomes to be used by all future trials examining 
therapeutic surgical interventions for gastric cancer 
is needed. This should consider the views of all key 
stakeholders, including patients.
IntrODuCtIOn 
background
Gastric cancer remains a leading cause of 
cancer-related death globally.1 Long-term 
survival remains poor and has not improved 
significantly over the last four decades.2 While 
there has been a shift to multimodal therapy 
over the last decade, surgery remains the 
primary method of curative treatment. Many 
developments in surgical techniques aim to 
improve long-term survival, while minimising 
postoperative complications. Understanding 
which of these approaches are optimal for 
patients should be based on robust evidence 
from well-designed trials. This process 
involves the synthesis of evidence in the 
form of systematic reviews which can only be 
reliably undertaken if trials report the same 
outcomes and measure them in the same 
manner.
This review forms part of the first stage of 
a three-stage study, which intends to examine 
and address problems with inconsistent 
outcome reporting in gastric cancer surgery 
trials (GASTROS: GAstric Cancer Surgery 
TRials Reported Outcome Standardisation). 
The study aims to develop a ‘core outcome 
set’ (COS)—a minimum group of stan-
dardised and well-defined outcomes, relevant 
to key stakeholders and measured by all trials3 
—to standardise the reporting of outcomes 
in randomised control trials within this field. 
Our previously published study protocol 
contains an overview of all three stages.4
Within our study protocol, we described the 
results from a ‘rapid review’ of gastric cancer 
surgery trials during a 24-month period 
which demonstrated significant variations 
strengths and limitations of this study
 ► This systematic review is the first to describe the 
variation in outcome reporting within the field of sur-
gical trials for gastric cancer.
 ► The study is based on a reproducible and transpar-
ent methodology which has been subjected to criti-
cal appraisal during a peer-review process.
 ► The study forms part of a larger project (the 
GASTROS study) to develop a ‘core outcome set’ for 
use in surgical trials for gastric cancer and was re-
viewed and funded by the National Institute of Health 
Research (UK).
 ► Only English-language and randomised studies 
were included in the analysis.
 ► Expanding the search may have resulted in the iden-
tification of other relevant outcomes reported in this 
field.
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in outcome reporting. We hypothesised that these varia-
tions were likely to represent a more widespread problem 
within this field. Inconsistencies in outcome reporting 
are prevalent within the medical literature and contribute 
significantly to ‘research waste’.5 Several reviews have 
demonstrated that trials within the same field often report 
different outcomes, define them poorly and use various 
outcome measurement instruments.6–9 This results in 
data which cannot be reliably compared or combined 
leading to further confusion within the evidence base. As 
such, initiatives such as Core Outcome Measures in Effec-
tiveness Trials (COMET) were formed to promote the 
development of COS to address these issues.3
With respect to surgical trials for gastric cancer, (1) no 
rigorous examination of outcome reporting has been 
previously undertaken and (2) there is no COS for use 
in this field.
Aims and objectives
This review aims to demonstrate whether further work 
to develop a COS to be used in surgical trials for gastric 
cancer is required. Specifically, the objectives are
1. To examine the degree of variation in the reporting 
of outcomes described by gastric cancer surgery trials.
2. To generate a ‘long list’ of potentially important out-
comes which will be prioritised during a Delphi survey 
in stage 2 of the study.
MethODs
Definitions
The GASTROS study, and more specifically this review, 
focuses on outcome reporting in ‘therapeutic surgical 
trials’. A ‘surgical trial’ has been previously defined as one 
of the following10:
 ► Type 1: A trial of medical interventions in surgical 
patients.
 ► Type 2: A trial which compares a surgical intervention 
to another surgical intervention.
 ► Type 3: A trial which compares a surgical intervention 
to a non-surgical intervention.
The GASTROS study focuses on ‘type 2’ trials due to the 
significant research activity within this field (a detailed 
justification can be found in our study protocol).4 In the 
context of gastric cancer, a ‘therapeutic surgical interven-
tion’ is defined as a potentially curative procedure which 
aims to excise the gastric neoplasm resulting in partial or 
total organ loss.
search strategy
A summary of the review’s inclusion and exclusion 
criteria is summarised in table 1, with details of our search 
strategy presented below. An example search algorithm 
for the MEDLINE via OVID database is presented in 
supplementary appendix 1.
Timeline
Trials were searched from 1996 when the first Consoli-
dated Standards of Reporting Trials statement for the 
reporting of randomised controlled trials (RCTs) was 
published up to and including March 2016. The COS 
aims to influence trial design regardless of the country of 
origin of participating centres and patients. Many of the 
surgical interventions (eg, D2 lymphadenectomy) which 
have recently been examined in the West have long been 
established practice in the Far East and Asia. Searching 
trials over a 20-year period allows a comprehensive under-
standing of which outcomes have been measured for 
similar trials regardless of the trial location.
Table 1 Inclusion and exclusion criteria for this review
Included Excluded
Types of 
studies
 ► Type 2* surgical randomised controlled trials 
(RCTs) and protocols of surgical RCTs (all trial 
phases).
 ► Systematic reviews of type 2 surgical RCTs.
 ► English-language studies
 ► Type 1 or type 3* surgical RCTs and systematic reviews 
of type 1 or type 3 RCTs
 ► Non-randomised studies
 ► Non-English-language studies
Population  ► Patients aged 18 years and over  ► Patients below the age of 18
Interventions  ► Partial or total gastrectomy
 ► Surgery with curative intent
 ► Oesophagectomy for gastro-oesophageal junctional 
tumours
 ► Surgery with non-curative intent (ie, in stage 4 cancer 
with prior expectation of an R1 or R2 resection) for the 
relief of symptoms such as gastric outlet obstruction or 
bleeding
 ► Endoscopic interventions
Conditions  ► Invasive cancer of the stomach and gastro-
oesophageal junction
 ► Dysplasia or non-invasive gastric neoplasms.
 ► Sarcoma (including gastrointestinal stromal tumours)
 ► Gastric lymphoma
*Type 1: a trial of medical interventions in surgical patients; type 2: a trial which compares a surgical intervention to another surgical 
intervention; type 3: a trial which compares a surgical intervention to a non-surgical intervention.10
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Identifying studies
Detailed search strategies were developed for each of the 
following electronic databases examined:
 ► Evidence Based Medicine Reviews via OVID
 – Cochrane Database of Systematic Reviews 2005 to 
30 March 2016.
 – ACP Journal Club 1991 to March 2016.
 – Database of Abstracts of Reviews of Effects 1st 
Quarter 2016.
 – Cochrane Central Register of Controlled Trials 
February 2016.
 – Health Technology Assessment 1st Quarter 2016.
 – NHS Economic Evaluation Database 1st Quarter 
2016.
 ► MEDLINE via OVID (1 January 1996 to 30 March 
2016).
 ► EMBASE via OVID (1 January 1996 to 30 March 2016).
 ► CINAHL via EBSCO (1 January 1996 to 30 March 
2016)
In order to identify surgical interventions and outcome 
measures being used in current studies, we searched 
the following databases for protocols of ongoing trials, 
including completed trials not yet published:
 ► The US National Institutes of Health Trials Register 
(http:// clinicaltrials. gov).
 ► The WHO International Clinical Trials Registry Plat-
form (http:// apps. who. int/ trialsearch/ default. aspx).
Non-English-language studies were excluded from this 
review due to resource limitations. Trials published only 
as conference abstracts were excluded as they are often 
limited by ‘word count’ and hence the abstract would not 
represent a comprehensive list of outcomes measured in 
the respective study.
Assessment of eligibility
For quality assurance, two review authors (BA and AMG) 
independently screened the titles and abstracts retrieved 
from the electronic searches. This assessment was under-
taken in groups of ten abstracts in reverse chronolog-
ical order. Once there was complete agreement with 
two consecutive groups of 10 abstracts, the remaining 
abstracts were split and each reviewer screened inde-
pendently. Full-text copies of all study publications that 
appeared to meet the inclusion criteria were obtained. 
Full-text copies were also obtained where there was insuf-
ficient information in the title or abstract to make a clear 
judgement. Systematic reviews of RCTs were also retrieved 
to find studies which had previously not been identified.
BA and AMG independently assessed the full-text 
copies for eligibility. This assessment was undertaken in 
groups of 10 publications in reverse chronological order. 
Once there was complete agreement with two consecutive 
groups of 10 abstracts, the remaining publications were 
split, and each reviewer extracted data independently. 
Any disagreements were resolved through discussion. 
There were no unresolved disagreements that required 
referral to the GASTROS study management team for a 
final decision.
Data extraction
BA and AMG independently reviewed all eligible publica-
tions and extracted data (described below) into a Micro-
soft Excel (V.2013, Microsoft, Washington, DC, USA) 
spreadsheet.
Publication versus study
It is not uncommon that investigators publish results at 
different stages of their trial and with each publication 
present a new set of outcomes. The GASTROS study team 
decided to amalgamate the outcomes published in all 
publications associated with a single trial to more fairly 
reflect outcomes being reported by research groups.
Trial characteristics
The following data were recorded for each trial:
1. Author details.
2. Title of publication.
3. Journal.
4. Year of publication.
5. Number of participating centres.
6. Country of first author.
7. Countries of participating centres.
8. Total number of patients recruited to the study.
9. Length of follow-up.
10. Interventions being investigated.
Outcomes
We defined an outcome as ‘a unique endpoint which 
attempts to describe health-related changes that occur 
secondary to a therapeutic intervention’.4 The following 
data were recorded for each outcome:
1. Outcome measured (and whether stated as primary or 
secondary outcome). Where a primary outcome was 
not explicitly stated, the outcome on which the sam-
ple size calculation was based was taken as the primary 
outcome.
2. Whether the outcome was defined or not. Outcomes 
were considered defined if text of their meaning or a 
citation was provided.
3. The definition of the outcome.
4. The method of outcome measurement (indicators 
and/or tools used, if relevant).
5. Time points and time period at or during which the 
outcome was measured (eg, quality of life at 3 months 
post surgery).
Merging outcomes and grouping under ‘themes’
Outcomes were extracted verbatim from publications and 
minimal merging of terms was undertaken. Outcomes 
were merged to accommodate for variant spellings of the 
same words. For example, ‘anastomotic leak’, ‘anasto-
motic leakage’ and ‘anastomotic leaks’ were merged into 
‘anastomotic leak’. The verbatim texts and merged terms 
were verified and authorised respectively by the study 
management group.
From the experience of other groups undertaking 
reviews of outcome reporting, the resulting lists of 
outcomes are generally extremely long and unwieldy.6 
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Consequently, developing a method to organise these 
outcomes has been necessary. The subject of taxonomy 
in outcome reporting, including hierarchical structure 
and which terms/definitions to use, is an emerging area 
of great significance. We set out our definitions a priori, 
which can be found in our study protocol.4 Many COS 
developers have organised their outcomes into broad cate-
gories with common ‘themes’. Our study is one of only a 
handful addressing outcome reporting in surgical trials 
related to the gastrointestinal (GI) tract. At the time of 
data analysis, we opted to group outcomes under ‘themes’ 
(detailed in table 2) similar to those described by other 
surgical COS.6–8 11 Doing so enables COS researchers to 
more readily understand trends in outcome reporting 
within the field of GI surgery. While the themes used in 
our review enable the reader to understand the types of 
outcomes being reported, this system has not been devel-
oped through wider consensus and has not been subject 
to a validation process.
At the time of writing, a broader taxonomy for outcome 
classification had been proposed.12 This system aims to 
address some of the ambiguity associated with outcome 
classification on a wider-scale and organises outcomes 
under 38 ‘outcomes domains’ which sit under five 
‘outcomes areas’ (‘mortality/survival’, ‘physiological/
clinical’, ‘life impact’, ‘resource use’ and ‘adverse events’). 
While the authors have demonstrated that this system is 
comprehensive and applicable to trials irrespective of the 
field being studied, they have called for further validation 
of their work.
Patient and public involvement
A Study Advisory Group (SAG) forms part of the manage-
ment structure of the wider GASTROS study,4 of which 
this review forms part of the first stage. The SAG is made 
up of key stakeholder representatives including patients, 
oncology nurses and surgeons. The group provides 
advice on the methodology of the study, general delivery 
of the study against its stated objectives and ensures that 
the viewpoints of all stakeholder groups are considered. 
The results of this systematic review were presented to a 
SAG meeting; the ensuing discussion influenced certain 
aspects of the results section within this paper such as the 
emphasis on patient-reported outcomes.
results
summary
A total of 1919 abstracts were screened which resulted in 
the identification of 48 publications from 32 trials (having 
recruited a total of 9073 patients) eligible for inclusion 
in the review (figure 1). A further 875 protocols were 
screened which identified 24 active or unpublished trials 
aiming to recruit 10 761 patients. A summary of all trials 
included in the analysis is described in table 3. During 
the data extraction process, no disagreements requiring 
Table 2 Number of times at least one outcome from respective theme was reported in published trials and unpublished or 
actively recruiting trial protocols
Outcome theme Theme definition
Published 
trials
(n=32)
(%)
Unpublished 
or actively 
recruiting 
trial protocols 
(n=23†) (%)
Cost Relating to delivery of surgery as part of clinical care within a 
healthcare system
1 (3) 5 (23)
Patient pathway Outcomes related to the flow of patients through the healthcare 
system (eg, hospital stay, readmission)
20 (63) 4 (17)
Patient-reported outcomes Outcomes taken from the patient perspective* 6 (19) 13 (57)
Surviving and controlling cancer Measures of disease recurrence or disease progression 15 (47) 17 (74)
Mortality Outcomes related to short-term and long-term survival/death 
rates and cause of death
27 (84) 19 (83)
Short-term mortality/perioperative death 27 (84) 10 (43) 
Long-term survival 13 (41) 19 (44) 
Technical aspects of surgery Outcomes recorded directly in the operating theatre (eg,
operation time, blood loss)
31 (97) 13 (57)
Recovery from surgery Report of patient condition following surgery and the ability to 
return to preoperative or premorbid state
16 (50) 9 (39)
Adverse events Forms of short-term and long-term postoperative complications 
following surgery
31 (97) 18 (78)
*Certain patient-reported outcomes may fall under other ‘themes’, for example, ‘postoperative pain’ may relate to ‘recovery from 
surgery’.
†One trial protocol contained no information about planned outcomes to report, therefore 23 out of total 24 trials were included in this 
table.
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discussion in the study management group arose between 
the two independent reviewers. A total of 749 (392 unique 
terms) outcomes were reported of which 13% (96 out 
of 749) were accompanied by an attempted definition. 
Thirty-eight per cent of trials (12 out of 32) described a 
primary outcome or provided a sample size calculation. 
No single outcome was reported in every trial.
Analysis of outcomes according to themes
Outcomes were organised into eight ‘outcome themes’, 
illustrated in figure 2 and described in table 2. A compre-
hensive list of reported outcomes is presented in supple-
mentary appendix 2. Below, we present a summary of 
some of the most commonly reported short-term and 
long-term outcome themes.
Mortality
Death after surgery was generally described as ‘short-term’ 
and ‘long-term’ survival. Long-term survival was used as 
a primary outcome measure in 41% of trials (13 out of 
32). The terms used to describe long-term mortality and 
the time points at which they were measured was inconsis-
tent (table 4). ‘Short-term’ mortality was reported by 84% 
of trials (27 out of 32) of which 15 provided one of the 
following definitions (frequency each definition was used 
is presented in brackets).
1. ‘Death within 30 days of surgery’ (3/15).
2. ‘Death of any cause within 30 days, or death within the 
same hospitalisation’ (9/15).
3. ‘In-hospital deaths and ‘deaths’ within 1 month’ 
(1/15).
4. ‘Death within 30 days of the operation or during any 
hospital stay’ (1/15).
5. ‘Any death that occurred during the hospital stay' 
(1/15).
Adverse events
Adverse events were the most common outcome theme 
to be reported and made up half of the 10 most reported 
outcomes (table 5). ‘Anastomotic leak’ was the most 
common adverse event to be reported and was described 
using five different definitions (frequency each definition 
was used is presented in brackets).
₋ ‘Clinical and radiological diagnosis’ (2).
₋ ‘Confirmed by gastrointestinal x-ray imaging, endos-
copy, or angiography’ (1).
₋ ‘Dehiscence confirmed by radiographic examination 
using contrast medium’ (1).
Figure 1 Study selection and inclusion.
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₋ ‘Type I anastomotic leakage: a small localised leakage 
at the oesophagojejunal anastomosis, without pleural or 
abdominal spillage, demonstrated by radiologic studies 
with barium’ (1).
₋ ‘Type II anastomotic leakage: an important dehis-
cence of the oesophago-jejunal anastomosis, with pleural 
or abdominal dissemination, appearance of intestinal 
content through the drains, a positive methylene blue test 
(appearance of orally ingested methylene blue through 
the drains), and clear demonstration of this leakage by 
radiologic contrast studies’ (1).
Adverse events were categorised by 12 out of 32 trials 
using terms including ‘major’, ‘minor’, ‘short-term’ and 
‘long-term’. Five trials used a formal classification system 
(Clavien-Dindo Classification or Accordian Severity 
Grading).
Figure 2 Outcome themes reported in (A) gastric cancer surgery trials and (B) in future trials based on study protocols.
Table 4 Reporting of ‘long-term mortality’ in gastric cancer surgery trials
Term used
Trials reporting 
outcome (n)
Follow-up period 
used
Frequency 
defined Definitions provided
‘Overall survival’ 
including ‘death 
from all causes’
19 Not described
3 years
5 years
6 years
7 years
10 years
7  ► Date of randomisation until the day of death or the 
day of last follow-up (censored)
 ► Date of surgery to the date of death from any cause, 
censoring the follow-up time at the most recent date 
for living patients
 ► Date of randomisation to the date of death
 ► Date of randomisation to the date of death from any 
cause
 ► Overall survival included operative deaths
 ► Overall survival excluded postoperative deaths
‘Survival’ 
including 
‘survival period’
13 Not described
5 years
11 years
4  ► Survival excluding operative mortality
 ► Survival 5 years after curative surgery
‘Disease-
specific survival’ 
including 
‘gastric cancer-
related deaths’
4 Not described
5 years
1  ► Proportion of patients who had not died from gastric 
cancer
Disease-free 
survival*
1 Not described 1  ► Time from randomisation to recurrence or death due 
to any cause
Recurrence-free 
survival*
2 Not described 2  ► Time from randomisation to either the first 
recurrence or death from any cause
 ► Time from randomisation to the first documentation 
of cancer recurrence or death from any cause
*Although these terms do not relate to mortality, they have been included in this table as the definitions provided by papers describe death as 
an end point.
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Patient-reported outcomes
Patient-reported outcomes (PROs) were reported in 19% 
of trials (6 out of 32) and included measures of quality 
of life (QoL) (n=3) and ‘pain’ (n=3). QoL was measured 
using validated tools for gastric cancer in two trials 
(EORTC QLQ-C30 with QLQ and Spitzer QoL Index) 
and a non-validated tool in one trial. Pain was measured 
using three different visual-analogue scales.
Multicentre trials
Forty per cent (13 out of 32) of studies were multicentre 
trials (table 2). Ninety-two per cent (12 out of 13) of 
trials stated a primary outcome measure (5-year overall 
survival, 5-year survival, all-cause mortality and 3-year 
disease-free survival). Sixteen per cent (63 out of 393) of 
all outcomes reported in these trials were accompanied 
by an attempted definition. PROs were reported in 23% 
of trials (3 out of 13) with 8% (1 out of 13) of studies 
reporting ‘QoL’ as an outcome.
Findings from study protocols
Most of the 24 ongoing or unpublished trials13–36 are 
recruiting in China (n=13), with 20 examining ‘extent 
of lymphadenectomy’ or minimally invasive approaches 
to surgery. A total of 220 uniquely termed outcomes 
are planned to be reported, 35 of which (16%) have an 
accompanying definition in the respective protocol. The 
most common term used to report ‘long-term survival’ is 
‘overall survival’ (OS) which will be measured by 16 trials. 
Seven of these trials plan to measure OS after 5 years of 
follow-up, three at 3 years of follow-up and six did not 
identify time points at which OS would be measured. At 
the time of our search, one trial protocol contained no 
information about which outcomes are to be measured.
QoL is due to be measured by 10 trials (42%) with 
five trials proposing to use one or a combination of four 
different measurement instruments (EORTC QLQ-C30 
with QLQ-STO22, SF-36, GIQLI and Euro-Quality of Life-
5D). Seven protocols described the timing of the quality 
of life measurements as follows:
 ► ‘Preoperative, postoperative 3 weeks and postopera-
tive 12 months’.
 ► ‘In pre-therapy <7 days, preoperative <7 days and post-
operative at 12 months after surgery’.
 ► ‘90th postoperative day’.
 ► ‘Regularly for 3 years after surgery’.
 ► ‘Preoperatively, 5 days postoperatively, 3 months, 
6 months and 1 year postoperatively’.
 ► ‘Baseline, 1 week, 1 month, 6 month, 1 year, 3 years’.
 ► ‘6 weeks, 12, 24, 36, 48 and 50 months after surgery’.
DIsCussIOn
This review is the first to examine the subject of outcome 
reporting in this field and demonstrates significant incon-
sistencies in the outcomes measured in trials examining 
therapeutic surgical interventions for gastric cancer. Not 
only is there disagreement about ‘what’ outcomes should 
be measured, but also ‘when’ and ‘how’ they should be 
measured. Consequently, undertaking meta-analyses 
and systematic reviews of these interventions becomes 
problematic and impacts negatively on the ability of 
researchers and clinicians to formulate robust clinical 
guidelines for the radical treatment of gastric cancer.
This problem is not confined to previously reported 
trials. Our analysis of outcome reporting in multicentre 
studies and review of active trial protocols has demon-
strated similar issues and further highlights the potential 
‘research waste’ within this field. Glasziou and Chambers 
Table 5 The 10 most frequently reported outcomes
Outcome Theme
Trials reporting 
outcome (n) Trials reporting the outcome*
Number of lymph nodes 
dissected/resected/retrieved
Technical aspects of surgery 22 2, 3, 5, 7, 9, 10, 13, 14, 15, 16, 17, 18, 19, 
20, 21, 23, 24, 25, 26, 29, 31, 32
Operative time Technical aspects of surgery 18 4, 5, 7, 8, 10, 11, 13, 14, 15, 16, 20, 22, 23, 
24, 25, 26, 27, 30
Anastomotic leak Adverse events 17 1, 2, 4, 6, 10, 14, 16, 17, 19, 22, 23, 24, 25, 
27, 28, 31, 32
Pancreatic fistula Adverse events 15 1, 2, 4, 5, 10, 16, 17, 19, 22, 23, 26, 27, 28, 
29, 32
Duration of hospital stay Patient pathway 12 1, 2, 5, 6, 7, 9, 13, 15, 20, 23, 26, 28
Duration of postoperative 
hospital stay
Recovery from surgery 11 2, 7, 9, 11, 14, 16, 19, 24, 25, 27, 32
Pneumonia Adverse events 11 7, 10, 11, 12, 17, 23, 27, 28, 29, 31, 32
‘5-year’ survival Mortality 11 1, 2, 6, 9, 10, 16, 17, 18, 19, 22, 26
Wound infection Adverse events 10 2, 6, 12, 15, 16, 18, 19, 22, 24, 28
Abdominal abscess Adverse events 10 5, 9, 10, 16, 17, 19, 23, 26, 28, 29
*See table 1 for trial numbers and associated publications.
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estimate that 85% of all biomedical research is ‘wasted’, 
and that a significant proportion of this can be attributed 
to problems choosing and reporting relevant outcomes in 
trials.5 Thus, if we combine the number of patients who 
have participated in gastric cancer surgery trials over the 
last two decades with those that actively recruiting trials 
wish to attract, a total of 20 000 patients may have partici-
pated in trials which, from a methodological perspective, 
could have had a far greater benefit and impact. Not only 
does this represent an inefficient use of time and scarce 
financial resource, but it may also have a longer-lasting 
negative impact on future trial participation by patients. 
Similar issues related to outcome reporting have been 
identified by several other groups supporting the theory 
that this is a widespread problem.6–8 11
Furthermore, if the methodology of a particular trial is 
not sufficiently robust or the outcomes reported are not 
relevant to key stakeholders, the natural course will be 
for other researchers to examine the same interventions 
again, using a different approach. If these subsequent 
trials do not address the underlying methodological 
issues, they only contribute to a perpetual cycle which 
serves to weaken the evidence base. This is reflected 
within the field of gastric cancer surgery where 13 trials 
have examined minimally invasive gastrectomy and a 
further 13 are actively recruiting to trials examining the 
same intervention.
Reported outcomes should be relevant to key stake-
holders including patients. Given the sheer volume of 
complications that are reported by gastric surgical trials, 
one may expect to find the impact on QoL is routinely 
reported. Indeed, QoL has been demonstrated as an 
important outcome to measure in other gastrointestinal 
cancer fields.37 This has certainly not been the case with 
gastric cancer surgery trials over the last two decades 
and while there seems to be a greater acceptance by 
trials currently in recruitment that QoL is important to 
measure (although this group still represents less than 
half of ongoing trials), there remains great variation in 
relation to ‘how’ and ‘when’ it is measured.
To address these inconsistencies, we believe that a 
COS is required for gastric cancer surgery studies. Devel-
oping a minimum reporting standard will contribute to 
maximising the benefits from randomised control trials 
which are expensive, labour intensive and logistically 
challenging to set up. A COS does not aim to restrict the 
outcomes that are reported, but merely to ensure that the 
most critical outcomes (as decided by key stakeholders) 
are clearly defined and measured uniformly.
The challenges associated with inconsistent outcome 
reporting in trials are certainly not confined to the field 
of gastric cancer. The COMET initiative database (http://
www. comet- initiative. org/ studies/ search) contains details 
of >400 completed, active or planned COS projects from 
across many different specialities.38 While experience 
within this relatively new research field has grown consid-
erably over the last decade, there is still much work to 
be done to further develop the various methodological 
approaches which can be applied. The GASTROS study 
aims to add to this in several ways including examining 
the role of ‘internationalising’ COS development by 
undertaking a multilanguage Delphi survey as part of a 
consensus-seeking process.
strengths and limitations
In addition to being the first systematic review to examine 
this subject, this study is based on a reproducible and 
transparent methodology which has been subjected to 
critical appraisal from a study management team and 
peer-review process; a protocol of the GASTROS study 
which aims to develop this COS has been published 
previously.4 Nonetheless, there are limitations. Including 
non-English and non-randomised studies in our search 
strategy may have identified other different outcomes 
reported in this field. However, when finalising our inclu-
sion criteria for this review, the two primary objectives of 
this review were considered: (1) to describe the current 
landscape of outcome reporting in gastric cancer surgery 
RCTs and (2) to take forward a ‘long list’ of outcomes to 
be prioritised (by means of a Delphi survey) to form the 
basis of a COS for RCTs. While we accept that such a COS 
would have benefits to non-RCTs and national audits, our 
primary focus was to improve the quality of RCTs and 
hence excluding other study types. In addition, there 
will be an opportunity during the Delphi survey (stage 
2 of the GASTROS study) for participants to add further 
outcomes (not already identified from this review) which 
key stakeholders deem important to be considered for 
prioritisation. A further limitation to this review was that 
it was not prospectively registered on a public database. 
However, as we describe above, the GASTROS study, 
including its scope and systematic review plan, has been 
peer-reviewed and published previously.4
In summary, the reporting of outcomes in gastric 
cancer surgery trials is inconsistent and there is large vari-
ation with respect to definitions, measurement tools and 
timing of measurement. This means that data cannot be 
synthesised efficiently. We believe that a COS to define a 
minimum set of standards to implement across all gastric 
surgical trial is warranted.
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